Moderna Stock Soars as Flu Reversal Ignites Hopes

Moderna ( (MRNA) ) has risen by 17.69%. Read on to learn why.

Moderna shares climbed 17.69% over the past week as investors reacted to a mix of regulatory progress and pipeline momentum across both vaccines and oncology. The key catalyst was the U.S. Food and Drug Administration’s reversal on Moderna’s mRNA-1010 seasonal flu vaccine filing, agreeing to formally review the application after initially issuing a Refusal-to-File letter earlier this month. With a decision date now set for August 5, 2026, the prospect of commercial launch for the 2026–2027 flu season has revived confidence that Moderna can convert its mRNA technology into another major revenue stream beyond COVID-19.

At the same time, sentiment was supported by news that Moderna is pushing deeper into cancer treatment, updating investors on its Phase 2 INTerpath-013 trial of V940 (mRNA-4157), an mRNA-based personalized cancer vaccine. The study, run in partnership with Merck, is testing V940 in combination with blockbuster immunotherapy Keytruda and chemotherapy as a first-line option for patients with metastatic squamous non-small cell lung cancer. The rigorously designed, randomized, triple-blind trial aims to show that adding V940 can improve survival over standard therapy alone, underscoring Moderna’s ambition to build a meaningful oncology franchise.

Despite the strong weekly move in Moderna’s stock, Wall Street remains cautious. Analysts currently rate the shares a Hold, with the average price target implying potential downside from recent levels, reflecting concerns that cash flows from newer products are still years away and trial outcomes remain uncertain. For now, traders are betting that regulatory green lights on flu and a high-upside, though longer-dated, oncology pipeline could mark an inflection point for Moderna’s mRNA platform – but future price action will hinge on clinical data, regulatory milestones, and the company’s ability to execute in a crowded and competitive healthcare landscape.